Vaccibody AS and Phibro Animal Health Corporation enter into Development and License Agreement

The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell novel vaccines for the poultry market using the Vaccibody platform technology. Under the agreement, Phibro and […]

Lytix presents at ASCO

Lytix Bioharma presents data at ASCO from the first LTX-315 clinical trial. Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics – Immunotherapy Poster Session’. The poster […]

Pharmaconutrition products for cancer patients

Smartfish is a Norwegian company developing synergistic omega 3 based pharmaconutrition products. Smartfih is now studying the effect of their phamaconutrition on the immune system, and would like to get in contact with Norwegian collaborators. Smartfish joined the Oslo Cancer Cluster in 2014 and currently have two products on the market that have been clinically […]

The Norwegian Cancer Society invest in Vaccibody

The Norwegian Cancer Society (NCS) have established an investment fund for Norwegian oncology companies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions, NCS has decided to place their first investment in Vaccibody. NCS will invest 500,000 euros. For publication in Norwegian, see Dagens Næringsliv. “We are very pleased to […]

NLSDAYS-ECCP 2014: Present your oncology innovation

Present your oncology innovation to the global life science industry at the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering (ECCP). Please note that application deadline is May 19th. 12 innovation projects will be selected to present a pitch. ECCP and the Nordic Life Science […]

Positive results on bile duct cancer from PCI Biotech

The PCI Biotech stock went straight up on the Norwegian Stock Exchange after successful results from the first dose cohort in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with inoperable bile duct cancer (cholangiocarcinoma). No safety concerns were observed at this dose level. PCI Biotech have previously […]